A recent study published in eClinicalMedicine evaluated a noninvasive urinary miRNA assay for detecting pancreatic cancer across all stages. Pancreatic cancer has a low survival rate due to late-stage diagnosis and limited screening tools. The study collected urine samples from pancreatic cancer patients and controls, isolating extracellular vesicles for miRNA analysis. A machine-learning model achieved high accuracy in detecting pancreatic cancer, outperforming the CA19-9 biomarker. The assay showed promise in early-stage detection, with potential to improve survival outcomes. Continued research is needed to validate and refine this approach for broader populations and stages of pancreatic cancer.
Source link
Innovative urine test could improve pancreatic cancer survival rates
